[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201992768A1 - Морфологические формы g1t38 и способы их получения - Google Patents

Морфологические формы g1t38 и способы их получения

Info

Publication number
EA201992768A1
EA201992768A1 EA201992768A EA201992768A EA201992768A1 EA 201992768 A1 EA201992768 A1 EA 201992768A1 EA 201992768 A EA201992768 A EA 201992768A EA 201992768 A EA201992768 A EA 201992768A EA 201992768 A1 EA201992768 A1 EA 201992768A1
Authority
EA
Eurasian Patent Office
Prior art keywords
producing
methods
morphological forms
isopropylpiperazin
pyrazino
Prior art date
Application number
EA201992768A
Other languages
English (en)
Inventor
Александр Смит
Ханна С. Уайт
Патрисия Андрес
Сюйфэн СУНЬ
Лэй Чжу
Петинка И. Влахова
Original Assignee
Г1 Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Г1 Терапьютикс, Инк. filed Critical Г1 Терапьютикс, Инк.
Publication of EA201992768A1 publication Critical patent/EA201992768A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Данное изобретение обеспечивает неожиданно стабильную, высококристаллическую форму 2'-((5-(4-изопропилпиперазин-1-ил)пиридин-2-ил)амино)-7',8'-дигидро-6'H-спиро[циклогексан-1,9'-пиразино[1',2':1,5]пирроло[2,3-d]пиримидин]-6'-она ди-HCl соли для полезной терапевтической эффективности фармацевтических препаратов и стабильности дозированной формы.
EA201992768A 2017-06-29 2018-06-29 Морфологические формы g1t38 и способы их получения EA201992768A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762526937P 2017-06-29 2017-06-29
PCT/US2018/040435 WO2019006393A1 (en) 2017-06-29 2018-06-29 MORPHIC FORMS OF GIT38 AND METHODS OF MAKING SAME

Publications (1)

Publication Number Publication Date
EA201992768A1 true EA201992768A1 (ru) 2020-05-19

Family

ID=64742232

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992768A EA201992768A1 (ru) 2017-06-29 2018-06-29 Морфологические формы g1t38 и способы их получения

Country Status (15)

Country Link
US (1) US11261193B2 (ru)
EP (2) EP3645001B1 (ru)
JP (2) JP2020526492A (ru)
KR (1) KR102659211B1 (ru)
CN (1) CN110913861B (ru)
AU (2) AU2018291026B2 (ru)
BR (1) BR112019027967A2 (ru)
CA (1) CA3067873A1 (ru)
EA (1) EA201992768A1 (ru)
FI (1) FI3645001T3 (ru)
IL (2) IL315143A (ru)
NZ (1) NZ759691A (ru)
RU (1) RU2019142591A (ru)
WO (1) WO2019006393A1 (ru)
ZA (1) ZA201907981B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110728A1 (es) 2017-01-06 2019-04-24 G1 Therapeutics Inc Terapia combinada para el tratamiento del cáncer
EP3738084A4 (en) * 2018-01-08 2021-11-17 G1 Therapeutics, Inc. G1T38 SUPERIOR DOSAGE RATES
CN114366743A (zh) * 2018-04-09 2022-04-19 G1治疗公司 具有驱动致癌突变的癌症的治疗
TW202128174A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
AU2021273744A1 (en) 2020-05-19 2022-12-08 G1 Therapeutics, Inc. Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
WO2021257587A1 (en) * 2020-06-15 2021-12-23 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
EP4225758A1 (en) * 2020-10-08 2023-08-16 Teva Pharmaceuticals International GmbH Solid state forms of trilaciclib and of trilaciclib salts

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US98402A (en) 1869-12-28 Improvement in devices for lubricating journals
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
AU749750B2 (en) 1997-02-05 2002-07-04 Warner-Lambert Company Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AP1911A (en) 2000-06-26 2008-10-30 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds.
WO2002003992A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
US20020016318A1 (en) 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
BR0112360A (pt) 2000-07-06 2003-05-06 Wyeth Corp Método para aumentar a atividade da sintase de óxido nìtrico
AU2001271782A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
WO2002003988A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
CA2414938A1 (en) 2000-07-06 2002-01-17 Simon Nicholas Jenkins Combinations of ssri and estrogenic agents
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
AU2001273125A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
MXPA02012896A (es) 2000-07-06 2003-10-24 Wyeth Corp Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos.
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
JP4490434B2 (ja) 2003-10-23 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 神経及び神経精神疾患の処置においてＧｌｙＴ−１阻害剤として使用するためのトリアザ−スピロピペリジン誘導体
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
JP2008512460A (ja) 2004-09-08 2008-04-24 メルク エンド カムパニー インコーポレーテッド 単環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬
ATE463245T1 (de) 2004-09-09 2010-04-15 Merck Sharp & Dohme Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
DE602005020656D1 (de) 2004-09-13 2010-05-27 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
US7399767B2 (en) 2005-01-21 2008-07-15 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
WO2007061677A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam aryl cgrp receptor antagonists
PT1984333E (pt) 2006-02-03 2012-07-16 Bionomics Ltd Benzofuranos, benzotiofenos, benzoselenofenos e indóis substituídos e sua utilização como inibidores da polimerização da tubulina
AU2007332898A1 (en) 2006-12-08 2008-06-19 Merck Sharp & Dohme Corp. Constrained spirocyclic compounds as CGRP receptor antagonists
WO2008109464A1 (en) 2007-03-02 2008-09-12 University Of Massachusetts Spirolactam targeting compounds and related compounds
JP2010531364A (ja) 2007-06-25 2010-09-24 ニューロジェン・コーポレーション ピペラジニルオキソアルキルテトラヒドロ−β−カルボリンおよび関連類似体
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
WO2010012777A1 (en) 2008-07-29 2010-02-04 Nerviano Medical Sciences S.R.L. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
JP5560496B2 (ja) 2008-08-22 2014-07-30 ノバルティス アーゲー Ｃｄｋ阻害剤としてのピロロピリミジン化合物
JP2012504645A (ja) 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
CN102231984A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
ES2561216T3 (es) 2009-05-13 2016-02-25 The University Of North Carolina At Chapel Hill Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
NZ598705A (en) 2009-09-16 2014-06-27 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
BR112012031464A2 (pt) 2010-06-10 2020-08-04 Aragon Pharmaceuticals, Inc. moduladores do receptor de estrogênio e os seus usos
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2012048058A2 (en) 2010-10-06 2012-04-12 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
PT2632467T (pt) 2010-10-25 2016-08-29 G1 Therapeutics Inc Inibidores cdk
US8691830B2 (en) * 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
US8829102B2 (en) 2010-10-27 2014-09-09 Cabot Corporation High loading carbon black masterbatch for pressure pipe applications
AU2011347718B2 (en) 2010-12-24 2016-06-23 Msd Oss B.V. N-substituted azetidine derivatives
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
KR20140101399A (ko) 2011-12-14 2014-08-19 세라곤 파마슈티컬스, 인크. 불화 에스트로겐 수용체 조절제 및 이의 용도
KR20140103335A (ko) 2011-12-16 2014-08-26 올레마 파마슈티컬스 인코포레이티드 신규한 벤조피란 화합물, 조성물 및 이의 용도
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
CA2870019C (en) 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
WO2013169574A2 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
WO2014004596A1 (en) 2012-06-26 2014-01-03 U.S. Coatings Ip Co. Llc Water-based coating compositions
KR102238970B1 (ko) * 2012-07-13 2021-04-09 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
WO2014019176A1 (zh) 2012-08-01 2014-02-06 华为技术有限公司 用于同步的方法、装置及系统
BR112015010035A2 (pt) 2012-11-01 2017-07-11 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
US20140274896A1 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
CN105473140B (zh) 2013-03-15 2018-04-10 G1治疗公司 在化学疗法期间对正常细胞的瞬时保护
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
DK3004090T3 (en) 2013-05-28 2018-01-08 Astrazeneca Ab CHEMICAL COMPOUNDS
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
KR20160021281A (ko) 2013-06-19 2016-02-24 세라곤 파마슈티컬스, 인크. 아제티딘 에스트로겐 수용체 조절제 및 이의 용도
PE20160157A1 (es) 2013-06-19 2016-03-18 Seragon Pharmaceuticals Inc Moduladores de los receptores de estrogeno y sus usos
WO2015061407A1 (en) 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
RU2016137122A (ru) 2014-03-13 2018-04-18 Ф. Хоффманн-Ля Рош Аг Терапевтические комбинации с модуляторами рецепторов эстрогена
US20150297606A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
TWI699363B (zh) 2014-12-18 2020-07-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并［３，４-ｂ］吲哚雌激素受體調節劑及其用途
WO2017021177A1 (en) * 2015-08-04 2017-02-09 Universitat De Barcelona Pharmaceutical combinations for use in the treatment of cancer
PT3386500T (pt) 2015-12-09 2023-01-06 Univ Illinois Supressores seletivos do recetor de estrogénio à base de benzotiofeno
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. TREATMENT OF EGFR MEDIATED CANCER WITH LESS SIDE EFFECTS

Also Published As

Publication number Publication date
JP2020526492A (ja) 2020-08-31
IL315143A (en) 2024-10-01
CN110913861A (zh) 2020-03-24
AU2018291026B2 (en) 2022-09-01
US20200123168A1 (en) 2020-04-23
AU2022279510A1 (en) 2023-02-02
JP2023123786A (ja) 2023-09-05
US20230043305A1 (en) 2023-02-09
FI3645001T3 (fi) 2024-09-25
EP3645001A1 (en) 2020-05-06
KR102659211B1 (ko) 2024-04-18
IL271543B1 (en) 2024-09-01
AU2018291026A1 (en) 2019-12-19
EP3645001A4 (en) 2020-12-02
ZA201907981B (en) 2023-04-26
RU2019142591A3 (ru) 2021-11-29
KR20200020893A (ko) 2020-02-26
RU2019142591A (ru) 2021-07-29
BR112019027967A2 (pt) 2020-07-14
IL271543A (en) 2020-02-27
US11261193B2 (en) 2022-03-01
WO2019006393A1 (en) 2019-01-03
NZ759691A (en) 2023-05-26
EP3645001B1 (en) 2024-07-03
CN110913861B (zh) 2024-01-09
EP4455146A2 (en) 2024-10-30
CA3067873A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
EA201992768A1 (ru) Морфологические формы g1t38 и способы их получения
CY1119502T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
EA201492176A1 (ru) Селективные ингибиторы pi3k дельта
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
MX2014010494A (es) Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
EA201690752A1 (ru) Ингибиторы g12c kras
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
SG10201803331PA (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
MA40236A (fr) Formes cristallines de (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanpyrido[1',2':4,5]pyrazino 2,1-b][1,3]oxazépine-10-carboxamide
MX2017001284A (es) Tieno [3,2-d] pirimidina, furo[3,2-d] pirimidina y pirrolo [3,2-d] pirimidinas utiles para el tratamiento de infecciones por virus sincitial respiratorio.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
IL288750A (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
EA201691385A1 (ru) Комбинированная терапия рака
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
EA201890922A1 (ru) Циклические простоэфирные производные пиразоло[1,5-а]пиримидин-3-карбоксамида
MX2017008430A (es) Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.
EA201990364A1 (ru) КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
EA202090385A1 (ru) Новые промежуточные соединения, используемые для синтеза производных аминопиримидина, способ их получения и способ получения производных аминопиримидина с их использованием
EA201990046A1 (ru) Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета
BR112018076622A2 (pt) pirrolo[2,3-d]piridazin-4-onas e pirazolo[3,4-d]piridazin-4-onas substituídas como inibidores de proteína cinase
EP3845231A4 (en) THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT
EA201790140A1 (ru) Фармацевтические лекарственные формы